Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Clinical use of St. John's wort

Robert B Saper, MD, MPH
Section Editor
Joann G Elmore, MD, MPH
Deputy Editor
Howard Libman, MD, FACP


St. John's wort (Hypericum perforatum) is a five petal yellow flower (picture 1) that has been used medicinally since antiquity [1]. It was commonly referred to as "Fuga Demonum" (the devil's scourge) since it was used to protect against demonic possession and "evil spirits" [2]. One of the earliest references to the name St. John's wort is noted in a Gaelic legend from the sixth century where the missionary St. Columba carried a piece of St. John's wort because of his high regard for St. John [1]. It is believed that the name may have been derived from the fact that the flowers bloom around June 24th, the birthday of St. John the Baptist. Wort represents the old English term for plant.

St. John's wort has been utilized mainly for its antidepressant activity, but also for its purported antiinflammatory and wound healing properties [3]. The 2007 National Health Interview Survey found a large decrease in St. John's wort use by adults in the United States [4]. In 2002, St. John's wort was the sixth most popular natural product in the United States, used by 2.2 percent of American adults [5]. In 2007, St. John's wort was not among the 20 most commonly used dietary supplements [4]. This decrease may reflect the public's response to interim news reports of negative clinical trials [6-8] and potentially harmful interactions with prescription drugs [9-22].

Patients considering the use of St. John's wort should be counseled and cautioned regarding evidence of effectiveness and safety, the variability and lack of regulation in St. John's wort products in the United States, and the potential for herb-drug interactions.


A number of compounds isolated from St. John's wort possess pharmacologic activity. Naphthodianthrones (hypericin, pseudohypericin, protohypericin, protopseudohypericin, and cyclopseudohypericin), flavonoids (quercetin, rutin, and luteolin), hyperforin, several amino acids, and tannins have been isolated [23].

Neuropsychiatric activity — The majority of in vitro studies of St. John's wort have attempted to define its neuropharmacology. Hyperforin and hypericin have been studied most extensively. Hypericin was originally thought to be the major active component for St. John's wort in depression; however, it is now believed that hyperforin and related compounds are mostly responsible for St. John's wort's effect on mood.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Dec 06, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Hobbs C. St. John's wort--ancient herbal protector. Pharm Hist 1990; 32:166.
  2. Pratt A. Wild Flowers, Society for Promoting Christian Knowledge, London 1853.
  3. St. John's Wort. In: Lawrence Review of Natural Products, Facts and Comparisons, St. Louis 1997.
  4. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; :1.
  5. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; :1.
  6. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978.
  7. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002; 287:1807.
  8. Fava M, Alpert J, Nierenberg AA, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25:441.
  9. Knüppel L, Linde K. Adverse effects of St. John's Wort: a systematic review. J Clin Psychiatry 2004; 65:1470.
  10. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000; 355:547.
  11. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355:548.
  12. Johne A, Brockmöller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66:338.
  13. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70:518.
  14. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94:1247.
  15. Smith PF, Bullock JM, Booker BM, et al. Induction of imatinib metabolism by hypericum perforatum. Blood 2004; 104:1229.
  16. Mueller SC, Uehleke B, Woehling H, et al. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004; 75:546.
  17. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57:592.
  18. Tannergren C, Engman H, Knutson L, et al. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75:298.
  19. Hebert MF, Park JM, Chen YL, et al. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004; 44:89.
  20. Eich-Höchli D, Oppliger R, Golay KP, et al. Methadone maintenance treatment and St. John's Wort - a case report. Pharmacopsychiatry 2003; 36:35.
  21. Mills E, Montori VM, Wu P, et al. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 2004; 329:27.
  22. Nieminen TH, Hagelberg NM, Saari TI, et al. St John's wort greatly reduces the concentrations of oral oxycodone. Eur J Pain 2010; 14:854.
  23. Bennett DA Jr, Phun L, Polk JF, et al. Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacother 1998; 32:1201.
  24. Müller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 31 Suppl 1:16.
  25. Singer A, Wonnemann M, Müller WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999; 290:1363.
  26. Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S54.
  27. Perovic S, Müller WE. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 1995; 45:1145.
  28. Müller WE, Rossol R. Effects of hypericum extract on the expression of serotonin receptors. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S63.
  29. Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericum extract. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S60.
  30. Muller WE, Schafer C. Johanniskraut: in-vitro Studie uber Hypericum-Extrakt, Hypericin und Kampferol. Deutsche Apotheker Zeitung 1996; 136:1015.
  31. Demisch, L, Nispel, J, Sielaff, T, et al. Influence of subchronic Hyperforat administration on melatonin production. Arbeitsgemeinschaft fur Neuro und Psychopharmakologie-symposium Abstracts, Nurnberg 1991.
  32. Winterhof H, Butterweck V, Nahrstedt A, et al. Phytopharmaka in Forschung unf klinischer Anwendung, Steinkopff Verlag GmbH and Co, Darmstadt, Germany 1995. p.S39.
  33. Negrash AK. Comparative study of chemotherapeutic and pharmacological properties of antimicrobial preparation from common St. John's Wort. Fitonsidy Mater Soveshch 1969; :198.
  34. Lopez-Bazzocchi I, Hudson JB, Towers GH. Antiviral activity of the photoactive plant pigment hypericin. Photochem Photobiol 1991; 54:95.
  35. Wood S, Huffman J, Weber N, et al. Antiviral activity of naturally occurring anthraquinones and anthraquinone derivatives. Planta Medica 1990; 56:651.
  36. Carpenter S, Kraus GA. Photosensitization is required for inactivation of equine infectious anemia virus by hypericin. Photochem Photobiol 1991; 53:169.
  37. Lavie G, Valentine F, Levin B, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci U S A 1989; 86:5963.
  38. Schinazi RF, Chu CK, Babu JR, et al. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res 1990; 13:265.
  39. Hudson JB, Lopez-Bazzocchi I, Towers GH. Antiviral activities of hypericin. Antiviral Res 1991; 15:101.
  40. Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci U S A 1988; 85:5230.
  41. Gaind KN, Ganjoo TN. Antibacterial principle of Hypericum perforatum Linn. Indian J Pharm 1959; 21:172.
  42. Shipochliev T, Dimitrov A, Aleksandrova E. [Anti-inflammatory action of a group of plant extracts]. Vet Med Nauki 1981; 18:87.
  43. Vasilchenko EA. Analgesic action of flavonoids of Rhododendron luteum Sweet, Hypericum perforatum L., Lespedeza bicolor Turcz, and L. hedysaroids (Pall.). ) Kitag Rastit Resur 1986; 22:12.
  44. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; :CD000448.
  45. Rapaport MH, Nierenberg AA, Howland R, et al. The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. J Psychiatr Res 2011; 45:931.
  46. Müller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 2004; 66:538.
  47. Volz HP, Murck H, Kasper S, Möller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002; 164:294.
  48. Al-Akoum M, Maunsell E, Verreault R, et al. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause 2009; 16:307.
  49. Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause 2010; 17:326.
  50. Weber W, Vander Stoep A, McCarty RL, et al. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA 2008; 299:2633.
  51. Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999; 130:510.
  52. Parsons A, Ingram J, Inglis J, et al. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation. Drug Alcohol Depend 2009; 102:116.
  53. Sood A, Ebbert JO, Prasad K, et al. A randomized clinical trial of St. John's wort for smoking cessation. J Altern Complement Med 2010; 16:761.
  54. Saito YA, Rey E, Almazar-Elder AE, et al. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol 2010; 105:170.
  55. Kasper S, Gastpar M, Möller HJ, et al. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol 2010; 25:204.
  56. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: A guide for health-care professionals, The Pharmaceutical Press, London 1996.
  57. Golsch S, Vocks E, Rakoski J, et al. [Reversible increase in photosensitivity to UV-B caused by St. John's wort extract]. Hautarzt 1997; 48:249.
  58. Brockmöller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 Suppl 2:94.
  59. Upton, R (ed). American Herbal Pharmacopoeia and Therapeutic Compendium. St. John's Wort Hypericum perforatum 1997.
  60. Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril 1999; 71:517.
  61. Kŭnchev K, Liutskanov D, Arsenov L. [Comparative studies of plans for controlling American foulbrood in public aviaries]. Vet Med Nauki 1981; 18:94.
  62. Moretti ME, Maxson A, Hanna F, Koren G. Evaluating the safety of St. John's Wort in human pregnancy. Reprod Toxicol 2009; 28:96.
  63. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286:208.
  64. Gordon RY, Becker DJ, Rader DJ. Reduced efficacy of rosuvastatin by St. John's Wort. Am J Med 2009; 122:e1.
  65. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999; 354:2014.
  66. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97:7500.
  67. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290:1500.
  68. Mannel M. Drug interactions with St John's wort : mechanisms and clinical implications. Drug Saf 2004; 27:773.
  69. Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62:29.
  70. Wong AH, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55:1033.
  71. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12:7.
  72. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S57.
  73. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313:253.
  74. Treatment of Depression–Newer Pharmacotherapies. Summary, Evidence Report/Technology Assessment: Number 7, March 1999. Agency for Health Care Policy and Research, Rockville, MD. Available at: www.ahcpr.gov/clinic/epcsums/deprsumm.htm (Accessed on August 08, 2005).
  75. www.fda.gov/bbs/topics/NEWS/2007/NEW01657.html (Accessed on October 09, 2007).